Saturday, October 31, 2026

Tesla And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

December 20, 2021

Tesla  And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

(VIANEWS) - Tesla (TSLA), CSX Corporation (CSX), Addus HomeCare Corporation (ADUS) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Tesla (TSLA)

37.7% sales growth and 15.64% return on equity

Tesla, Inc. designs, develops, manufactures, leases, and sells electric vehicles, and energy generation and storage systems in the United States, China, Netherlands, Norway, and internationally.

Tesla's sales growth this year is anticipated to be 58.9% and 35.7% for next year.

Year-on-year quarterly revenue growth grew by 56.8%, now sitting on 46.85B for the twelve trailing months.

Volume

Today's last reported volume for Tesla is 5332880 which is 79.61% below its average volume of 26158200.

Tesla's sales growth for the next quarter is 37.7%. The company's growth estimates for the current quarter and the next is 81.6% and 102.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.64%.

Volatility

Tesla's last day, last week, and last month's current intraday variation average was 0.61%, 5.18%, and 3.61%, respectively.

Tesla's highest amplitude of average volatility was 5.68% (day), 5.55% (last week), and 5.14% (last month), respectively.

Tesla's Stock Yearly Top and Bottom Value

Tesla's stock is valued at $908.54 at 10:22 EST, way under its 52-week high of $1,243.49 and way above its 52-week low of $539.49.

Tesla's Moving Average

Tesla's worth is below its 50-day moving average of $1,006.49 and way above its 200-day moving average of $758.25.

Previous days news about Tesla(TSLA)

  • Tesla and these stocks are seeing the highest interest on wallstreetbets today. According to Benzinga on Wednesday, 15 December, "What Happened: Exchange-traded fund SPDR S&P 500 ETF Trust (NYSE:SPY) is seeing the highest interest on the forum with 528 mentions as at press time, followed by Tesla with 289 mentions, data from Quiver Quantitative showed.", "Electric vehicle maker Tesla Inc. (NASDAQ:TSLA) has emerged as the most-discussed stock on Reddit's r/WallStreetBets forum as of early Wednesday."
  • According to Bloomberg Quint on Wednesday, 15 December, "In October, Tesla became one of just a few companies to hit the $1 trillion valuation mark. "
  • According to Benzinga on Wednesday, 15 December, "Baby Floki Doge, named after Tesla Inc. (NASDAQ:TSLA) CEO Elon Musk's pet dog Floki, is a multi-chain cryptocurrency on the Binance & Ethereum Smart Chain network.", "Read Next: Elon Musk Says Tesla Will Try Out Doge Payment For Some Merchandise; Meme Currency Spikes In Reaction"
  • According to Bloomberg Quint on Wednesday, 15 December, "At a virtual bar, a giant cat in a dress served me pancakes, while a medieval knight talked about the engine capacity of Tesla Inc.'s Roadster with a cactus who nodded in agreement."
  • According to Benzinga on Wednesday, 15 December, "The entrepreneur said Tuesday that Tesla "will make some merch buyable with Doge & see how it goes."

2. CSX Corporation (CSX)

13% sales growth and 27.85% return on equity

CSX Corporation, together with its subsidiaries, provides rail-based freight transportation services.

CSX Corporation's sales growth this year is expected to be 14.7% and 7.7% for next year.

Year-on-year quarterly revenue growth grew by 24.3%, now sitting on 11.92B for the twelve trailing months.

Volume

Today's last reported volume for CSX Corporation is 29595700 which is 135.24% above its average volume of 12580700.

CSX Corporation's sales growth for the next quarter is 13%. The company's growth estimates for the current quarter and the next is 25% and 14.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 27.85%.

Volatility

CSX Corporation's last day, last week, and last month's current intraday variation average was 2.38%, 0.84%, and 1.33%, respectively.

CSX Corporation's highest amplitude of average volatility was 2.58% (day), 1.44% (last week), and 2.01% (last month), respectively.

CSX Corporation's Stock Yearly Top and Bottom Value

CSX Corporation's stock is valued at $35.72 at 10:22 EST, under its 52-week high of $36.45 and way higher than its 52-week low of $27.70.

CSX Corporation's Moving Average

CSX Corporation's worth is above its 50-day moving average of $33.43 and higher than its 200-day moving average of $32.80.

3. Addus HomeCare Corporation (ADUS)

12.6% sales growth and 7.6% return on equity

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States.

Addus HomeCare Corporation's sales growth this year is anticipated to be 13.3% and 8.6% for next year.

Year-on-year quarterly revenue growth grew by 11.7%, now sitting on 835.85M for the twelve trailing months.

Volume

Today's last reported volume for Addus HomeCare Corporation is 278452 which is 145.01% above its average volume of 113646.

Addus HomeCare Corporation's sales growth for the next quarter is 12.6%. The company's growth estimates for the present quarter and the next is 13.4% and 27%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.6%.

Volatility

Addus HomeCare Corporation's last day, last week, and last month's current intraday variation average was 4.24%, 2.01%, and 2.70%, respectively.

Addus HomeCare Corporation's highest amplitude of average volatility was 5.69% (day), 4.72% (last week), and 4.53% (last month), respectively.

Addus HomeCare Corporation's Stock Yearly Top and Bottom Value

Addus HomeCare Corporation's stock is valued at $90.67 at 10:22 EST, way below its 52-week high of $129.01 and way higher than its 52-week low of $73.06.

Addus HomeCare Corporation's Moving Average

Addus HomeCare Corporation's value is under its 50-day moving average of $90.85 and below its 200-day moving average of $92.54.

4. NeoGenomics (NEO)

12.1% sales growth and 5.42% return on equity

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia.

NeoGenomics's sales growth this year is anticipated to be 9% and 16% for next year.

Year-on-year quarterly revenue growth declined by 3.3%, now sitting on 484.59M for the twelve trailing months.

Volume

Today's last reported volume for NeoGenomics is 1058800 which is 6.36% above its average volume of 995407.

NeoGenomics's sales growth for the next quarter is 12.1%. The company's growth estimates for the ongoing quarter and the next is a negative 200% and negative -275%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.42%.

Volatility

NeoGenomics's last day, last week, and last month's current intraday variation average was 6.07%, 3.76%, and 3.74%, respectively.

NeoGenomics's highest amplitude of average volatility was 8.82% (day), 7.15% (last week), and 6.11% (last month), respectively.

NeoGenomics's Stock Yearly Top and Bottom Value

NeoGenomics's stock is valued at $30.49 at 10:22 EST, way below its 52-week high of $61.57 and higher than its 52-week low of $30.15.

NeoGenomics's Moving Average

NeoGenomics's value is way under its 50-day moving average of $42.27 and way below its 200-day moving average of $44.96.

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com